Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02774226 · ClinicalTrials.gov registry record · Phase 2
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by Augusta University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02774226 is a Phase 2 study that has completed, run by Augusta University. The registered enrollment target is 15 participants.
The verdict
NCT02774226, a Phase 2 study, has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Chronic obstructive pulmonary disease (COPD) affects up to 14 million people and is among the top five leading causes of death worldwide. Although COPD is a disease of the lungs, recent evidence indicates that COPD is associated with multiple systemic consequences including vascular endothelial dysfunction. Recently, it has been suggested that more patients with COPD die from cardiovascular disease and coronary heart disease than of direct pulmonary complications. Examination of the mechanisms that contribute to a reduction nitric oxide (NO) bioavailability resulting in vascular endothelial dysfunction in patients with COPD are important as endothelial dysfunction has been indicated to be an independent predictor of future atherosclerotic cardiovascular disease and events.
Interventions
- DRUG Tetrahydrobiopterin (BH4)
- DIETARY_SUPPLEMENT Antioxidant Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02774226
The ClinicalTrials.gov registry entry for NCT02774226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tetrahydrobiopterin (BH4) is the first listed.
NCT02774226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02774226 about?
NCT02774226 is a clinical study titled "Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease". Chronic obstructive pulmonary disease (COPD) affects up to 14 million people and is among the top five leading causes of death worldwide. Although COPD is a disease of the lungs, recent evidence indicates that COPD is associated with multiple systemic consequences including vascular endothelial dysf...
What is the current status of trial NCT02774226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2015-09. Estimated completion is 2018-07-30.
What interventions are being tested in trial NCT02774226?
The interventions under investigation include: Tetrahydrobiopterin (BH4) (DRUG), Antioxidant Cocktail (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02774226?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.